Maxim Group acted as co-manager on Immunovaccine’s $8.7 million follow-on offering

Halifax, Nova Scotia; September 4, 2014 – Immunovaccine Inc. (“Immunovaccine”, “IMV”, or the “Company”) (TSX-V: IMV), a clinical stage vaccine and immunotherapy company, has closed the previously announced public offering (the “Offering”), raising gross proceeds of $9,514,543. Under the terms of the Offering, a total of 9,153,300 units (the “Units”) were issued at a price of $0.95 per unit (the “Issue Price”) for gross proceeds of $8,695,635 with the balance of the proceeds resulting from the partial exercise of the over-allotment option, as described below. Each Unit consists of one common share in the share capital of Immunovaccine (a “Common Share”) and one-half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each whole Warrant entitles the holder thereof to purchase one additional Common Share upon payment of the exercise price of $1.24 per share until March 4, 2016.

This entry was posted in Uncategorized. Bookmark the permalink.